1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia (Q42100360)

From Wikidata

Jump to navigation Jump to search

scientific article published on December 13, 2010

Language	Label	Description	Also known as
English	1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia	scientific article published on December 13, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia (English)

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia (English)

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

Soluble epoxide hydrolase

0 references

D Euan MacIntyre

20

object named as

D Euan MacIntyre

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

author name string

Sampath-Kumar Anandan

1

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Heather Kay Webb

2

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Dawn Chen

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Yi-Xin Jim Wang

4

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sylvaine Cases

6

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Ying Cheng

7

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Upasana Mehra

9

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Vinh Tran

10

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Jon Vincelette

11

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Joanna Waszczuk

12

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Kathy White

13

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Le-Ning Zhang

15

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Randall Whitcomb

19

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

James Sabry

21

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Richard Gless

22

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Basker R. Aavula

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

Zung N. Do

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

Kenneth R. Wong

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

Paul D. Jones

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

Bruce D. Hammock

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

Dinesh V. Patel

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

language of work or name

0 references

publication date

13 December 2010

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

full work available at URL

https://europepmc.org/articles/pmc3529200?pdf=render

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

https://europepmc.org/articles/PMC3529200

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

https://europepmc.org/articles/PMC3529200?pdf=render

Portable Document Format

online access status

content deliverer

Europe PubMed Central

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

https://doi.org/10.1016/j.bmcl.2010.12.042

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21211973

21 November 2024

https://api.elsevier.com/content/article/PII:S0960894X10017968?httpAccept=text/xml

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

https://api.elsevier.com/content/article/PII:S0960894X10017968?httpAccept=text/plain

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

Bioorganic & Medicinal Chemistry Letters

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

21

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

3

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

983-988

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Rapid synthesis of an array of trisubstituted urea-based soluble epoxide hydrolase inhibitors facilitated by a novel solid-phase method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Soluble epoxide hydrolase inhibitors: a patent review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Inflammatory lipid mediators in adipocyte function and obesity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Insulin resistance and endothelial dysfunction: Are epoxyeicosatrienoic acids the link?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Expression and regulation of soluble epoxide hydrolase in adipose tissue

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Soluble epoxide hydrolase, a target with multiple opportunities for cardiovascular drug discovery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Discovery of spirocyclic secondary amine-derived tertiary ureas as highly potent, selective and bioavailable soluble epoxide hydrolase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Action of epoxyeicosatrienoic acids on cellular function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Emerging role of epoxyeicosatrienoic acids in coronary vascular function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Soluble epoxide hydrolase is a therapeutic target for acute inflammation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

29 May 2018

Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor γ in endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Effects of epoxyeicosatrienoic acids on levels of eNOS phosphorylation and relevant signaling transduction pathways involved

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3529200

17 August 2018

Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary metabolites of rimantadine in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Functional implications of a newly characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolism of a novel CCK-B antagonist in rat, dog and human liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/21211973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs).

33

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

Interspecies pharmacokinetics and in vitro metabolism of SQ109.

45

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

Drug Metabolism and Disposition

50

16

773

author name string

Fukuda

publication date

1988

1 reference

10.1016/J.BMCL.2010.12.042

https://api.crossref.org/works/10.1016/J.BMCL.2010.12.042

21 November 2024

Identifiers

10.1016/J.BMCL.2010.12.042

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42100360&oldid=2277937646"